Download PDF
Semin Thromb Hemost 2004; 30(3): 305-314
DOI: 10.1055/s-2004-831043
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Percutaneous Interventions in Patients with Immune-Mediated Heparin-Induced Thrombocytopenia

Eugenia Nikolsky1 , George D. Dangas1
  • 1Cardiovascular Research Foundation and the Lenox Hill Heart and Vascular Institute, New York, New York
Further Information

Publication History

Publication Date:
29 July 2004 (online)

    Permissions and Reprints

The use of unfractionated heparin, the traditional antithrombotic agent during percutaneous coronary interventions (PCI), is associated with the risk of heparin-induced thrombocytopenia, a rare but often fatal clinical condition. This article focuses on several issues related to heparin-induced immune-mediated thrombocytopenia (HIT, type II) and alternative modes of periprocedural anticoagulation in patients with suspected or known HIT.

The hypercoagulable state characterizing HIT, along with mechanical plaque disruption resulting from PCI place patients with HIT at particular risk of thrombosis during PCI. Given that a diagnosis of HIT precludes any further use of heparin, other treatment modalities are essential. Direct thrombin inhibitors are the drugs of choice in this challenging situation. These agents offer several advantages as anticoagulants for patients with HIT: (1) the ability to inhibit both thrombin that is bound to fibrin (clot-bound thrombin) and fluid-phase free thrombin; (2) rapid achievement of steady state; and (3) no cross-reactivity with HIT antibodies. Recent data on the use of bivalirudin, lepirudin, and argatroban in the setting of PCI in patients with HIT are encouraging. Optimal dosing regimens for argatroban, lepirudin, and bivalirudin should be further established in PCI patients.

KEYWORDS

Heparin - thrombocytopenia - direct thrombin inhibitors - heparin-induced thrombocytopenia - HIT

REFERENCES

  • 1 Brieger D B, Mak K H, Kottke-Marchant K, Topol E J. Heparin-induced thrombocytopenia.  J Am Coll Cardiol. 1998;  31 1449-1459
    CrossrefPubMedGoogle Scholar
  • 2 Warkentin T E. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia.  Arch Pathol Lab Med. 2002;  126 1415-1423
    PubMedGoogle Scholar
  • 3 Bell W R, Royall R M. Heparin-associated thrombocytopenia: a comparison of three heparin preparations.  N Engl J Med. 1980;  303 902-907
    PubMedGoogle Scholar
  • 4 Warkentin T E, Levine M N, Hirsh J et al.. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.  N Engl J Med. 1995;  332 1330-1335
    CrossrefPubMedGoogle Scholar
  • 5 Brushwood D B. Hospital liable for allergic reaction to heparin used in injection flush.  Am J Hosp Pharm. 1992;  49 1491-1492
    PubMedGoogle Scholar
  • 6 Heeger P S, Backstrom J T. Heparin flushes and thrombocytopenia.  Ann Intern Med. 1986;  105 143
    PubMedGoogle Scholar
  • 7 Laster J, Silver D. Heparin-coated catheters and heparin-induced thrombocytopenia.  J Vasc Surg. 1988;  7 667-672
    PubMedGoogle Scholar
  • 8 Cruz D, Karlsberg R, Takano Y, Vora D, Tobis J. Subacute stent thrombosis associated with a heparin-coated stent and heparin-induced thrombocytopenia.  Catheter Cardiovasc Interv. 2003;  58 80-83
    PubMedGoogle Scholar
  • 9 Lee D P, Warkentin T E. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. 2nd ed. New York; Marcel Dekker 2001: 87-121
    Google Scholar
  • 10 Warkentin T E, Sheppard J A, Horsewood P, Simpson P J, Moore J C, Kelton J G. Impact of the patient population on the risk for heparin-induced thrombocytopenia.  Blood. 2000;  96 1703-1708
    CrossrefPubMedGoogle Scholar
  • 11 Hirsh J, Warkentin T E, Shaughnessy S G et al.. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety?.  Chest. 2001;  119 (1 suppl) 64-94
    CrossrefPubMedGoogle Scholar
  • 12 Warkentin T E, Kelton J G. Temporal aspects of heparin-induced thrombocytopenia.  N Engl J Med. 2001;  344 1286-1292
    CrossrefPubMedGoogle Scholar
  • 13 Lubenow N, Kempf R, Eichner A, Eichler P, Carlsson L E, Greinacher A. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or re-exposure to heparin.  Chest. 2002;  122 37-42
    CrossrefPubMedGoogle Scholar
  • 14 Warkentin T E, Kelton J G. Delayed-onset heparin-induced thrombocytopenia and thrombosis.  Ann Intern Med. 2001;  135 502-506
    CrossrefPubMedGoogle Scholar
  • 15 Alban S, Greinacher A. Role of sulfated polysaccharides in the pathogenesis of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. 2nd ed. New York; Marcel Dekker 2001: 167-187
    Google Scholar
  • 16 Admiral J, Meter D. Heparin-dependent antigens in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. 2nd ed. New York; Marcel Dekker 2001: 137-148
    Google Scholar
  • 17 Boshkov L K, Warkentin T E, Hayward C P, Andrew M, Kelton J G. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies.  Br J Haematol. 1993;  84 322-328
    PubMedGoogle Scholar
  • 18 Cines D B, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia.  N Engl J Med. 1987;  316 581-589
    CrossrefPubMedGoogle Scholar
  • 19 Warkentin T E, Hayward C P, Boshkov L K et al.. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia.  Blood. 1994;  84 3691-3699
    CrossrefPubMedGoogle Scholar
  • 20 Warkentin T E. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia.  Transfus Med Rev. 1996;  10 249-258
    PubMedGoogle Scholar
  • 21 Burgess J K, Lindeman R, Chesterman C N, Chong B H. Single amino acid mutation of Fc gamma receptor is associated with the development of heparin-induced thrombocytopenia.  Br J Haematol. 1995;  91 761-766
    PubMedGoogle Scholar
  • 22 Warkentin T E. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. 2nd ed. New York; Marcel Dekker 2001: 43-86
    Google Scholar
  • 23 Singer R L, Mannion J D, Bauer T L, Armenti F R, Edie R N. Complications from heparin-induced thrombocytopenia in patients undergoing cardiopulmonary bypass.  Chest. 1993;  104 1436-1440
    PubMedGoogle Scholar
  • 24 Guittard M, Pradalier A, Vincent D, Dry J. Right intraventricular thrombosis and thrombopenia due to heparin.  Presse Med. 1988;  17 871
    PubMedGoogle Scholar
  • 25 Arthur C K, Grant S J, Murray W K, Isbister J P, Stiel J N, Lauer C S. Heparin-associated acute adrenal insufficiency.  Aust N Z J Med. 1985;  15 454-455
    PubMedGoogle Scholar
  • 26 Laster J, Cikrit D, Walker N, Silver D. The heparin-induced thrombocytopenia syndrome: an update.  Surgery. 1987;  102 763-770
    PubMedGoogle Scholar
  • 27 Cimo P L, Moake J L, Weinger R S, Ben-Menachem Y B, Khalil K G. Heparin-induced thrombocytopenia: association with a platelet aggregating factor and arterial thromboses.  Am J Hematol. 1979;  6 125-133
    PubMedGoogle Scholar
  • 28 Warkentin T E. Heparin-induced skin lesions.  Br J Haematol. 1996;  92 494-497
    CrossrefPubMedGoogle Scholar
  • 29 King D J, Kelton J G. Heparin-associated thrombocytopenia.  Ann Intern Med. 1984;  100 535-540
    PubMedGoogle Scholar
  • 30 Matthai Jr W H. Use of argatroban during percutaneous coronary interventions in patients with heparin-induced thrombocytopenia.  Semin Thromb Hemost. 1999;  25 (suppl 1) 57-60
    PubMedGoogle Scholar
  • 31 Campbell K R, Mahaffey K W, Lewis B E et al.. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.  J Invasive Cardiol. 2000;  12(suppl F) 14F-19F
    PubMedGoogle Scholar
  • 32 Bates E R. Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes.  Curr Cardiol Rep. 2001;  3 348-354
    PubMedGoogle Scholar
  • 33 Mahaffey K W. Anticoagulation for acute coronary syndromes and percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.  Curr Cardiol Rep. 2001;  3 362-370
    PubMedGoogle Scholar
  • 34 Manfredi J A, Wall R P, Sane D C, Braden G A. Lepirudin as a safe alternative for effective anticoagulation in patients with known heparin-induced thrombocytopenia undergoing percutaneous coronary intervention: case reports.  Catheter Cardiovasc Interv. 2001;  52 468-472
    PubMedGoogle Scholar
  • 35 Lewis B E, Matthai Jr W H, Cohen M, Moses J W, Hursting M J, Leya F. ARG-216/310/311 Study Investigators. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.  Catheter Cardiovasc Interv. 2002;  57 177-184
    CrossrefPubMedGoogle Scholar
  • 36 Cochran K, DeMartini T J, Lewis B E et al.. Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia.  J Invasive Cardiol. 2003;  15 617-621
    PubMedGoogle Scholar
  • 37 Mahaffey K W, Lewis B E, Wildermann N M et al.. ATBAT Investigators . The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results.  J Invasive Cardiol. 2003;  15 611-616
    PubMedGoogle Scholar
  • 38 Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin.  Circulation. 2001;  103 1479-1484
    PubMedGoogle Scholar
  • 39 Greinacher A, Volpel H, Janssens U et al.. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study.  Circulation. 1999;  99 73-80
    CrossrefPubMedGoogle Scholar
  • 40 Greinacher A, Janssens U, Berg G et al.. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators.  Circulation. 1999;  100 587-593
    CrossrefPubMedGoogle Scholar
  • 41 Eichler P, Friesen H J, Lubenow N, Jaeger B, Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance.  Blood. 2000;  96 2373-2378
    PubMedGoogle Scholar
  • 42 Hafner G, Rupprecht H J, Luz M et al.. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.  Eur Heart J. 1996;  17 1207-1215
    PubMedGoogle Scholar
  • 43 Laubenthal F C, Grosch B, Szurawitzki G, Sabin G V. Heparin-induced thrombocytopenia type II with early aortocoronary bypass occlusion and stent thrombosis after PTCA of the RCA-treatment with lepirudin (Refludan) and abciximab (Reopro) during recanalization of the RCA [in German].  Z Kardiol. 1999;  88 141-146
    CrossrefPubMedGoogle Scholar
  • 44 Pinto D S, Sperling R T, Tu T M, Cohen D J, Carrozza Jr J P. Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.  Catheter Cardiovasc Interv. 2003;  58 65-68
    PubMedGoogle Scholar
  • 45 Serruys P W, Herrman J P, Simon R et al.. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators.  N Engl J Med. 1995;  333 757-763
    CrossrefPubMedGoogle Scholar
  • 46 Hauptmann J. Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs. A review of small-molecule thrombin inhibitors.  Eur J Clin Pharmacol. 2002;  57 751-758
    CrossrefPubMedGoogle Scholar
  • 47 Matsuo T, Koide M, Kario K. Development of argatroban, a direct thrombin inhibitor, and its clinical application.  Semin Thromb Hemost. 1997;  23 517-522
    PubMedGoogle Scholar
  • 48 Lewis B E, Wallis D E, Leya F, Hursting M J, Kelton J G. Argatroban-915 Investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.  Arch Intern Med. 2003;  163 1849-1856
    CrossrefPubMedGoogle Scholar
  • 49 Lewis B E, Wallis D E, Berkowitz S D et al.. ARG-911 Study Investigators. . Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.  Circulation. 2001;  103 1838-1843
    CrossrefPubMedGoogle Scholar
  • 50 Reichert M G, MacGregor D A, Kincaid E H, Dolinski S Y. Excessive argatroban anticoagulation for heparin-induced thrombocytopenia.  Ann Pharmacother. 2003;  37 652-654
    CrossrefPubMedGoogle Scholar
  • 51 Lewis B E, Matthai Jr W H, Cohen M, Moses J W, Hursting M J, Leya F. ARG-216/310/311 Study Investigators . Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.  Catheter Cardiovasc Interv. 2002;  57 177-184
    CrossrefPubMedGoogle Scholar
  • 52 Sciulli T M, Mauro V F. Pharmacology and clinical use of bivalirudin.  Ann Pharmacother. 2002;  36 1028-1041
    CrossrefPubMedGoogle Scholar
  • 53 White H D, Aylward P E, Frey M J et al.. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators.  Circulation. 1997;  96 2155-2161
    PubMedGoogle Scholar
  • 54 Bittl J A, Chaitman B R, Feit F, Kimball W, Topol E J. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study.  Am Heart J. 2001;  142 952-959
    CrossrefPubMedGoogle Scholar
  • 55 Lincoff A M, Bittl J A, Harrington R A et al.. REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.  JAMA. 2003;  289 853-863
    CrossrefPubMedGoogle Scholar
  • 56 Lincoff A M, Kleiman N S, Kottke-Marchant K et al.. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).  Am Heart J. 2002;  143 847-853
    CrossrefPubMedGoogle Scholar
  • 57 Pothoulakis A J, Neerukonda S K, Ansel G, Jantz R D. Ancrod for coronary angioplasty.  Tex Heart Inst J. 1995;  22 342-346
    PubMedGoogle Scholar
  • 58 Moore J A, Burket M W, Puri S, Temesy-Armos P, Lachant N, Skeel R. Ancrod infusion for anticoagulation during and after PTCA in a patient with heparin-induced thrombocytopenia.  Cathet Cardiovasc Diagn. 1994;  32 286-287
    PubMedGoogle Scholar
  • 59 Lathan L O, Staggers S L. Ancrod: the use of snake venom in the treatment of patients with heparin-induced thrombocytopenia and thrombosis undergoing coronary artery bypass grafting: nursing management.  Heart Lung. 1996;  25 451-462
    PubMedGoogle Scholar
  • 60 Prentice C R, Hampton K K, Grant P J, Nelson S R, Nieuwenhuizen W, Gaffney P J. The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products.  Br J Haematol. 1993;  83 276-281
    PubMedGoogle Scholar
  • 61 Greinacher A, Amiral J, Dummel V, Vissac A, Kiefel V, Mueller-Eckhardt C. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay.  Transfusion. 1994;  34 381-385
    CrossrefPubMedGoogle Scholar
  • 62 Leroy J, Leclerc M H, Delahousse B et al.. Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216).  Semin Thromb Hemost. 1985;  11 326-329
    PubMedGoogle Scholar
  • 63 Gouault-Heilmann M, Huet Y, Adnot S et al.. Low molecular weight heparin fractions as an alternative therapy in heparin-induced thrombocytopenia.  Haemostasis. 1987;  17 134-140
    PubMedGoogle Scholar
  • 64 Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific.  Thromb Haemost. 1992;  67 545-549
    PubMedGoogle Scholar
  • 65 Warkentin T E, Kelton J G. Interaction of heparin with platelets, including heparin-induced thrombocytopenia. In: Bounameaux H Low-Molecular-Weight Heparins in Prophylaxis and Therapy of Thromboembolic Diseases New York; Marcel Dekker 1994: 75-127
    Google Scholar
  • 66 Chong B H, Ismail F, Cade J, Gallus A S, Gordon S, Chesterman C N. Heparin-induced thrombocytopenia: studies with a new low-molecular-weight heparinoid, Org 10172.  Blood. 1989;  73 1592-1596
    PubMedGoogle Scholar
  • 67 Magnani H N. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172).  Thromb Haemost. 1993;  70 554-561
    PubMedGoogle Scholar
  • 68 Hale L P, Smith K, Braden G A, Owen J. Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia.  Cathet Cardiovasc Diagn. 1998;  45 318-322
    CrossrefPubMedGoogle Scholar
  • 69 Cantor W J, Leblanc K, Garvey B, Watson K R, Rasymas A, Strauss B H. Combined use of Orgaran and Reopro during coronary angioplasty in patients unable to receive heparin.  Catheter Cardiovasc Interv. 1999;  46 352-355
    PubMedGoogle Scholar
  • 70 Reverter J C, Beguin S, Kessels H, Kumar R, Hemker H C, Coller B S. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and “clinical restenosis”.  J Clin Invest. 1996;  98 863-874
    CrossrefPubMedGoogle Scholar

George D DangasM.D. Ph.D. 

Cardiovascular Research Foundation

55 E. 59th Street, 6th Floor

New York, NY 10022

Email: gdangas@crf.org

      >